Inhibition of pancreatic adenocarcinoma cell growth by lovastatin

Shoichiro Sumi, R. Daniel Beauchamp, Courtney Townsend, Tatsuo Uchida, Manabu Murakami, Srinivasan Rajaraman, Jin Ishizuka, James C. Thompson

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

RAS protein (p21 ras) requires farnesyl (an intermediate of cholesterol synthesis) for activation. Activating mutations of K-ras gene have been detected in most human pancreatic adenocarcinomas. In the present study, the effect of lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A, the rate-limiting enzyme of cholesterol synthesis, on the growth of five pancreatic cancer cell lines (human-CAV, MIA Paca2, CAPAN2 and PANC1, and hamster-H2T) in vitro and of two cell lines (CAV and H2T) in vivo was examined. Inhibition of cell growth was observed with lovastatin doses at or above 2.5 μg/mL for H2T, CAV, MIA Paca2, and CAPAN2 or 10 μg/mL in PANC1. The H2T cell line was studied further to determine the reversibility of growth inhibition. Mevalonic acid (1 mmol/L) reversed lovastatin-induced inhibition of cell growth if it was added with lovastatin (2.5 μg/mL). Similarly, removal of lovastatin from the medium within 24 hours after treatment allowed recovery of cell growth. The effect of lovastatin on cell growth was irreversible after 48 hours of exposure. The survival fraction of H2T cells was markedly decreased by 1- or 24-hour exposure to 75 μg/mL but not to doses ranging from 0.5 to 60 μg/mL of lovastatin. Growth of pancreatic carcinoma xenografts (CAV and H2T) in nude mice was inhibited by a subcutaneous infusion of lovastatin (50 μg/h). These results indicate that mevalonic acid or a metabolite in the cholesterol synthesis pathway is necessary for growth of pancreatic cancer cells and suggest that lovastatin should be further examined as a potential therapeutic agent for pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)982-989
Number of pages8
JournalGastroenterology
Volume103
Issue number3
StatePublished - 1992

Fingerprint

Lovastatin
Adenocarcinoma
Growth
Pancreatic Neoplasms
Mevalonic Acid
Cholesterol
Cell Line
Proto-Oncogene Proteins p21(ras)
Subcutaneous Infusions
ras Genes
Heterografts
Nude Mice
Cricetinae
Mutation
Survival

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Sumi, S., Beauchamp, R. D., Townsend, C., Uchida, T., Murakami, M., Rajaraman, S., ... Thompson, J. C. (1992). Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology, 103(3), 982-989.

Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. / Sumi, Shoichiro; Beauchamp, R. Daniel; Townsend, Courtney; Uchida, Tatsuo; Murakami, Manabu; Rajaraman, Srinivasan; Ishizuka, Jin; Thompson, James C.

In: Gastroenterology, Vol. 103, No. 3, 1992, p. 982-989.

Research output: Contribution to journalArticle

Sumi, S, Beauchamp, RD, Townsend, C, Uchida, T, Murakami, M, Rajaraman, S, Ishizuka, J & Thompson, JC 1992, 'Inhibition of pancreatic adenocarcinoma cell growth by lovastatin', Gastroenterology, vol. 103, no. 3, pp. 982-989.
Sumi S, Beauchamp RD, Townsend C, Uchida T, Murakami M, Rajaraman S et al. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology. 1992;103(3):982-989.
Sumi, Shoichiro ; Beauchamp, R. Daniel ; Townsend, Courtney ; Uchida, Tatsuo ; Murakami, Manabu ; Rajaraman, Srinivasan ; Ishizuka, Jin ; Thompson, James C. / Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. In: Gastroenterology. 1992 ; Vol. 103, No. 3. pp. 982-989.
@article{ee6a905e8ae44ee898630b0dcd039f9e,
title = "Inhibition of pancreatic adenocarcinoma cell growth by lovastatin",
abstract = "RAS protein (p21 ras) requires farnesyl (an intermediate of cholesterol synthesis) for activation. Activating mutations of K-ras gene have been detected in most human pancreatic adenocarcinomas. In the present study, the effect of lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A, the rate-limiting enzyme of cholesterol synthesis, on the growth of five pancreatic cancer cell lines (human-CAV, MIA Paca2, CAPAN2 and PANC1, and hamster-H2T) in vitro and of two cell lines (CAV and H2T) in vivo was examined. Inhibition of cell growth was observed with lovastatin doses at or above 2.5 μg/mL for H2T, CAV, MIA Paca2, and CAPAN2 or 10 μg/mL in PANC1. The H2T cell line was studied further to determine the reversibility of growth inhibition. Mevalonic acid (1 mmol/L) reversed lovastatin-induced inhibition of cell growth if it was added with lovastatin (2.5 μg/mL). Similarly, removal of lovastatin from the medium within 24 hours after treatment allowed recovery of cell growth. The effect of lovastatin on cell growth was irreversible after 48 hours of exposure. The survival fraction of H2T cells was markedly decreased by 1- or 24-hour exposure to 75 μg/mL but not to doses ranging from 0.5 to 60 μg/mL of lovastatin. Growth of pancreatic carcinoma xenografts (CAV and H2T) in nude mice was inhibited by a subcutaneous infusion of lovastatin (50 μg/h). These results indicate that mevalonic acid or a metabolite in the cholesterol synthesis pathway is necessary for growth of pancreatic cancer cells and suggest that lovastatin should be further examined as a potential therapeutic agent for pancreatic cancer.",
author = "Shoichiro Sumi and Beauchamp, {R. Daniel} and Courtney Townsend and Tatsuo Uchida and Manabu Murakami and Srinivasan Rajaraman and Jin Ishizuka and Thompson, {James C.}",
year = "1992",
language = "English (US)",
volume = "103",
pages = "982--989",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Inhibition of pancreatic adenocarcinoma cell growth by lovastatin

AU - Sumi, Shoichiro

AU - Beauchamp, R. Daniel

AU - Townsend, Courtney

AU - Uchida, Tatsuo

AU - Murakami, Manabu

AU - Rajaraman, Srinivasan

AU - Ishizuka, Jin

AU - Thompson, James C.

PY - 1992

Y1 - 1992

N2 - RAS protein (p21 ras) requires farnesyl (an intermediate of cholesterol synthesis) for activation. Activating mutations of K-ras gene have been detected in most human pancreatic adenocarcinomas. In the present study, the effect of lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A, the rate-limiting enzyme of cholesterol synthesis, on the growth of five pancreatic cancer cell lines (human-CAV, MIA Paca2, CAPAN2 and PANC1, and hamster-H2T) in vitro and of two cell lines (CAV and H2T) in vivo was examined. Inhibition of cell growth was observed with lovastatin doses at or above 2.5 μg/mL for H2T, CAV, MIA Paca2, and CAPAN2 or 10 μg/mL in PANC1. The H2T cell line was studied further to determine the reversibility of growth inhibition. Mevalonic acid (1 mmol/L) reversed lovastatin-induced inhibition of cell growth if it was added with lovastatin (2.5 μg/mL). Similarly, removal of lovastatin from the medium within 24 hours after treatment allowed recovery of cell growth. The effect of lovastatin on cell growth was irreversible after 48 hours of exposure. The survival fraction of H2T cells was markedly decreased by 1- or 24-hour exposure to 75 μg/mL but not to doses ranging from 0.5 to 60 μg/mL of lovastatin. Growth of pancreatic carcinoma xenografts (CAV and H2T) in nude mice was inhibited by a subcutaneous infusion of lovastatin (50 μg/h). These results indicate that mevalonic acid or a metabolite in the cholesterol synthesis pathway is necessary for growth of pancreatic cancer cells and suggest that lovastatin should be further examined as a potential therapeutic agent for pancreatic cancer.

AB - RAS protein (p21 ras) requires farnesyl (an intermediate of cholesterol synthesis) for activation. Activating mutations of K-ras gene have been detected in most human pancreatic adenocarcinomas. In the present study, the effect of lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A, the rate-limiting enzyme of cholesterol synthesis, on the growth of five pancreatic cancer cell lines (human-CAV, MIA Paca2, CAPAN2 and PANC1, and hamster-H2T) in vitro and of two cell lines (CAV and H2T) in vivo was examined. Inhibition of cell growth was observed with lovastatin doses at or above 2.5 μg/mL for H2T, CAV, MIA Paca2, and CAPAN2 or 10 μg/mL in PANC1. The H2T cell line was studied further to determine the reversibility of growth inhibition. Mevalonic acid (1 mmol/L) reversed lovastatin-induced inhibition of cell growth if it was added with lovastatin (2.5 μg/mL). Similarly, removal of lovastatin from the medium within 24 hours after treatment allowed recovery of cell growth. The effect of lovastatin on cell growth was irreversible after 48 hours of exposure. The survival fraction of H2T cells was markedly decreased by 1- or 24-hour exposure to 75 μg/mL but not to doses ranging from 0.5 to 60 μg/mL of lovastatin. Growth of pancreatic carcinoma xenografts (CAV and H2T) in nude mice was inhibited by a subcutaneous infusion of lovastatin (50 μg/h). These results indicate that mevalonic acid or a metabolite in the cholesterol synthesis pathway is necessary for growth of pancreatic cancer cells and suggest that lovastatin should be further examined as a potential therapeutic agent for pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026671888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026671888&partnerID=8YFLogxK

M3 - Article

C2 - 1499946

AN - SCOPUS:0026671888

VL - 103

SP - 982

EP - 989

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 3

ER -